Evidence map›Paper›PMID 34079286›Full record

ArticleOncoTargets and therapy2021

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Ling Peng, Kui Xiao, Jian Cui, Xiang-Hua Ye, Yong-Chang Zhang, Li Mao, Giovanni Selvaggi, Jennifer Yen, Justin Stebbing

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 3 countries.

Ling Peng *Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, People's Republic of China.ORCID 0000-0002-1359-4982
Kui Xiao *Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Jian CuiShanghai BioGenius Bioinformatics Institute, Shanghai, People's Republic of China.
Xiang-Hua YeDepartment of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Yong-Chang ZhangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, People's Republic of China.ORCID 0000-0002-6829-7176
Li MaoBetta Pharmaceuticals, Hangzhou, People's Republic of China.
Giovanni SelvaggiX-Covery Holdings, Palm Beach Gardens, FL, USA.ORCID 0000-0001-8015-8999
Jennifer YenGuardant Health, Inc., Redwood City, CA, USA.
Justin StebbingDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-1117-6947
Betta Pharmaceuticals (China) · CNCentral South University · CNGuardant (United States) · USHangzhou First People's Hospital · CNHunan Cancer Hospital · CNImperial College London · GBShanghai Center For Bioinformation Technology · CNXcovery (United States) · USZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects. CASE PRESENTATION: Here, we report a case of a patient with NSCLC with an

conclusionThis is the first report of ensartinib treatment after alectinib-induced hyperbilirubinemia which was successfully relieved by ALSS treatment and targeted drug cessation.

Indexed as

alectinibALKensartinibhyperbilirubinemiaNSCLC

Identifiers

PMID34079286
PMCPMC8164872
OpenAlexW3165838714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.